ClinicalTrials.gg
CompletedNCT07266688Updated Apr 23, 2026

Evaluation of Bactorinol® Nasal Spray in Adult Patients With Vasomotor Rhinitis

An interventional study of Bactorinol® Nasal Spray and Isotonic Saline Solution in Vasomotor Rhinitis, sponsored by Liaquat University of Medical & Health Sciences. Completed at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Liaquat University of Medical & Health Sciences · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study aims to evaluate the effectiveness and safety of Bactorinol® nasal spray, a medical device containing winterized Pistacia lentiscus oil, in adults with vasomotor rhinitis. Vasomotor rhinitis is a chronic condition characterized by nasal congestion, rhinorrhea, and impaired nasal airflow.

In this multicenter, prospective, randomized, controlled clinical trial, 100 adult participants will be assigned in a 1:1 ratio to receive either Bactorinol® nasal spray or isotonic saline solution for 20 consecutive days. The primary objective is to determine whether Bactorinol® improves nasal airflow, measured by Peak Nasal Inspiratory Flow (PNIF). Secondary objectives include evaluating changes in symptoms and quality of life using the SNOT-22 questionnaire, assessing nasal cytology, and monitoring treatment compliance and adverse events.

The results of this study may help identify a non-pharmacological, natural-extract-based treatment option for patients with vasomotor rhinitis.

Read the detailed description

Vasomotor rhinitis is a chronic inflammatory condition of the nasal mucosa characterized by airflow obstruction, dysregulated mucus production, and impaired mucociliary clearance. Environmental factors, mucosal dryness, and alterations in epithelial function contribute to symptoms, and current treatment options are often limited or unsatisfactory.

Bactorinol® nasal spray is a medical device formulated with winterized Pistacia lentiscus oil, which contains terpenes and polyphenols with recognized emollient, anti-inflammatory, antibacterial, and antibiofilm properties. These characteristics may help reduce mucosal irritation, improve mucociliary function, and relieve nasal congestion.

This multicenter, prospective, randomized, controlled, parallel-group clinical trial will enroll 100 adults with a confirmed diagnosis of vasomotor rhinitis. Participants will be randomized 1:1 to receive either Bactorinol® nasal spray (3 puffs per nostril, three times daily) or isotonic saline solution with the same dosing schedule, for 20 days.

The primary endpoint is the change in nasal airflow as measured by Peak Nasal Inspiratory Flow (PNIF) from baseline to the end of treatment. Secondary assessments include changes in quality of life measured by the SNOT-22 questionnaire, nasal cytology via rhinocytogram, treatment compliance, and adverse events. Clinical and cytological evaluations will be performed at baseline and at the end of the 20-day treatment period.

The study is designed to determine whether Bactorinol® provides clinically meaningful improvement in nasal breathing and symptom burden in patients with vasomotor rhinitis and to assess its safety and tolerability when used as directed.

02

Conditions studied

  • Vasomotor Rhinitis
03

In context

Lead sponsor

Liaquat University of Medical & Health Sciences is the lead sponsor of 57 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged 18 to 70 years.
  • Confirmed diagnosis of vasomotor rhinitis.
  • Ability to understand the study procedures and provide written .
  • Ability to follow study instructions.
  • Availability to undergo scheduled evaluations.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women.
  • Stenosing deviation of the nasal septum.
  • Current or recurrent episodes of epistaxis.
  • History of nasal endoscopic surgery within the past 6 months.
  • Use of systemic antibiotics within the previous 30 days.
  • Known to any component of the study products.
  • Concomitant topical medications applied to the nasal mucosa.
  • Participation in another clinical trial or completion of another trial within the last month.
  • Failure or unwillingness to provide .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Bactorinol® Nasal Spray (Treatment Arm)

    Participants receive Bactorinol® nasal spray containing winterized Pistacia lentiscus oil (medical device). Dosage: 3 puffs per nostril, three times daily for 20 consecutive days.

    Device: Bactorinol® Nasal Spray

  • Active comparator
    Isotonic Saline Solution (Control Arm)

    Participants receive isotonic saline solution nasal spray. Dosage: 3 administrations per nostril, three times daily for 20 consecutive days.

    Other: Isotonic Saline Solution

Interventions

  • DeviceBactorinol® Nasal Spray

    Bactorinol® nasal spray containing winterized Pistacia lentiscus oil. Administered as 3 puffs per nostril, three times daily for 20 consecutive days.

    Also known as: Winterized Pistacia lentiscus oil nasal spray

  • OtherIsotonic Saline Solution

    Isotonic saline nasal spray administered as 3 sprays per nostril, three times daily for 20 consecutive days.

    Also known as: Normal saline nasal spray (Control)

06

What researchers measure

Primary outcomes

  1. Change in Peak Nasal Inspiratory Flow (PNIF)

    PNIF will be measured using a Peak Nasal Inspiratory Flow meter to assess nasal airflow. The value at baseline (Visit 1) will be compared with the value at the end of treatment (Visit 2).

    Time frame: 20 days

Secondary outcomes

  1. Change in Quality of Life Measured by SNOT-22

    Quality of life will be assessed using the validated Sino-Nasal Outcome Test (SNOT-22) questionnaire at baseline and at the end of treatment.

    Time frame: 20 days

  2. Change in Nasal Cytology (Rhinocytogram)

    Nasal cytology will be evaluated using a rhinocytogram, assessing quantitative and semi-quantitative cellular components including neutrophils, metachromatic cells, goblet cells, eosinophils, mast cells, bacteria, spores/fungi, and presence of biofilm.

    Time frame: 20 days

  3. Treatment Compliance

    Compliance will be assessed by counting returned product at the end of treatment and verifying the number of nebulizations performed.

    Time frame: 20 days

  4. Incidence of Adverse Events

    All adverse events reported by participants or observed by investigators during the study period will be recorded.

    Time frame: 20 days

07

Study locations

1 site
  • Università di Urbino Carlo Bo
    Urbino, Pesaro E Urbino 61029, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Apr 2026, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 5, 2025
StartActual
Dec 1, 2025
Primary completionActual
Apr 20, 2026
CompletionActual
Apr 20, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07266688
Lead sponsor
Liaquat University of Medical & Health Sciences
Collaborators
University of Urbino "Carlo Bo"
Responsible party
Dr. Amjad Khan (Professor of Clinical Biochemistry and Experimental Medicine, Liaquat University of Medical & Health Sciences) — Principal investigator
First posted
Dec 5, 2025
Start date
Dec 1, 2025
Primary completion
Apr 20, 2026
Completion
Apr 20, 2026
Last update
Apr 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion